Research Blog

Peptide Research Briefings

Weekly updates on clinical trials, regulatory developments, and breakthrough research in peptide therapeutics. Evidence-based analysis with full citations.

155
Articles
6
Categories
Weekly
Updates

Featured

Featured
Weekly Briefing Jan 31, 2026

Research Identifies New Growth Hormone Secretagogue with Improved Safety

Scientists report a novel growth hormone secretagogue peptide that stimulates physiological GH release while avoiding the metabolic side effects associated with existing compounds.

#growth-hormone #secretagogue #ghrp +2
6 min read

Latest Posts

Guide Feb 18, 2026

Best Peptides for Weight Loss in 2026: Evidence-Based Rankings

Evidence-ranked review of peptides for weight management in 2026. Only FDA-approved and late-stage clinical compounds, ranked by strength of evidence — not marketing claims.

#weight-loss #glp-1 #peptides +5
6 min read
Safety Feb 18, 2026

Is BPC-157 Safe? What the Evidence Actually Shows

An honest evidence review of BPC-157 safety. What human data exists, what is still only in animals, what the FDA's stance is, and what the significant gaps in our knowledge mean for evaluating this widely discussed peptide.

#bpc-157 #safety #peptide-safety +2
7 min read
Deep Dive Feb 18, 2026

Retatrutide Phase 3 Results: What the TRIUMPH Program Data Shows

Evidence review of retatrutide's TRIUMPH phase 3 program. What the triple GLP-1/GIP/glucagon agonist data shows for weight loss and metabolic health, and how phase 2 results compare to the emerging phase 3 picture.

#retatrutide #triple-agonist #glp-1 +5
7 min read
Deep Dive Feb 18, 2026

Semaglutide vs Tirzepatide: What the Evidence Says in 2026

A head-to-head evidence comparison of semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) — covering mechanisms, weight loss data from STEP and SURMOUNT trials, SURMOUNT-5 head-to-head results, cardiovascular outcomes, and what the evidence actually says about choosing between them.

#semaglutide #tirzepatide #glp-1 +4
7 min read
Weekly Briefing Jan 29, 2026

Peptide-Based Biosensor Enables Rapid Pathogen Detection

Researchers develop a rapid diagnostic platform using antimicrobial peptides as recognition elements, enabling point-of-care detection of bacterial pathogens within minutes.

#biosensor #antimicrobial-peptide #diagnostics +1
6 min read
Weekly Briefing Jan 27, 2026

Tirzepatide Shows Reduced Cancer Incidence in Observational Study

Large observational analysis suggests tirzepatide may be associated with reduced obesity-related cancer incidence, adding to evidence of benefits beyond weight loss.

#tirzepatide #cancer #obesity +2
6 min read
Weekly Briefing Jan 23, 2026

GLP-1 Agonist Access Expanding Through Telehealth Platforms

Telehealth platforms have emerged as a major channel for GLP-1 agonist prescribing, expanding access but raising questions about appropriate patient selection and monitoring.

#glp-1 #telehealth #access +2
6 min read
Weekly Briefing Jan 21, 2026

Research Reveals Pentapeptide Promotes Hair Follicle Regeneration

Scientists identify a novel pentapeptide that activates hair follicle stem cells and promotes hair regrowth in preclinical and early clinical studies.

#pentapeptide #hair-loss #regeneration +2
6 min read
Weekly Briefing Jan 19, 2026

Survodutide Moves Toward FDA Submission for MASH

Boehringer Ingelheim announces plans to submit survodutide for FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), based on positive phase 2 results.

#survodutide #mash #nafld +2
6 min read
Weekly Briefing Jan 16, 2026

Peptide-Drug Conjugate Platform Shows Success in Solid Tumors

A novel peptide-drug conjugate platform demonstrates promising efficacy across multiple solid tumor types, expanding the targeted delivery approach beyond antibody-drug conjugates.

#peptide-drug-conjugate #oncology #solid-tumors +1
6 min read
Weekly Briefing Jan 14, 2026

DSIP Sleep Study: 22% More Deep Sleep Without Sedation

A 4-week randomized trial found DSIP increased slow-wave sleep by 22% and sleep efficiency to 86% — with no next-day sedation. Evidence grade: low — single trial, needs replication.

#dsip #sleep #neuropeptide +2
6 min read
Weekly Briefing Jan 12, 2026

Orforglipron Oral GLP-1 Non-Peptide Agonist Shows 14% Weight Loss

Updated ATTAIN program data confirms orforglipron achieves 14% weight loss without injection, validating the non-peptide oral GLP-1 approach for obesity treatment.

#orforglipron #oral-glp1 #obesity +2
6 min read
Weekly Briefing Jan 9, 2026

Research Shows Thymulin Peptide Enhances Vaccine Response in Elderly

New research demonstrates that thymulin supplementation can restore vaccine responsiveness in older adults, addressing a critical gap in immune function that develops with aging.

#thymulin #vaccine #immunosenescence +2
6 min read
Weekly Briefing Jan 7, 2026

FDA Issues Draft Guidance for Peptide Stability Testing

The FDA has released comprehensive draft guidance on stability testing requirements for peptide drug products, providing clearer expectations for manufacturers and potentially streamlining development.

#fda #regulatory #stability-testing +2
7 min read
Weekly Briefing Jan 5, 2026

Retatrutide Phase 3 Results Confirm Triple-Agonist Superiority

Eli Lilly announces positive topline results from the TRIUMPH phase 3 program, with retatrutide demonstrating unprecedented weight loss efficacy in adults with obesity.

#retatrutide #phase-3 #triple-agonist +2
6 min read
Weekly Briefing Jan 2, 2026

New Year Brings Expanded GLP-1 Manufacturing Capacity Online

Major pharmaceutical manufacturers have activated new production facilities for GLP-1 agonists, promising to ease supply constraints that limited patient access throughout 2024-2025.

#glp-1 #manufacturing #drug-supply +2
6 min read
Weekly Briefing Dec 31, 2025

Year-End Analysis: Peptide Market Trends and 2026 Outlook

A comprehensive analysis of peptide therapeutic market performance in 2025 and key trends shaping the industry outlook for 2026 and beyond.

#market-analysis #2026-outlook #peptide-industry +1
6 min read
Weekly Briefing Dec 29, 2025

2025 Peptide Drug Approvals: 12 FDA Clearances, Record Year

The FDA approved 12 peptide-based therapeutics in 2025 — surpassing the previous record of 9. Breakdown by therapeutic area, driving factors, and pipeline outlook for 2026.

#fda-approval #peptide-drugs #2025-review +1
6 min read
Weekly Briefing Dec 26, 2025

Peptide Delivery via Microneedle Patch Advances to Clinical Trials

A novel microneedle patch system for peptide delivery has entered clinical trials, promising painless, self-administered peptide therapy without traditional injections.

#drug-delivery #microneedle #peptide-technology +1
6 min read
Weekly Briefing Dec 24, 2025

Research Identifies New Natriuretic Peptide Variant for Heart Failure Treatment

Scientists have identified a novel natriuretic peptide variant that shows improved stability and efficacy in preclinical heart failure models, potentially addressing limitations of current therapies.

#natriuretic-peptide #heart-failure #cardiovascular +1
6 min read
Weekly Briefing Dec 22, 2025

Year in Review: GLP-1 Agonists Dominate Peptide Therapeutics in 2025

As 2025 draws to a close, GLP-1 agonists have cemented their position as the most transformative class in peptide therapeutics, reshaping treatment paradigms across multiple conditions.

#glp-1 #semaglutide #tirzepatide +3
6 min read
Weekly Briefing Dec 19, 2025

Peptide Antibiotic Candidate Shows Activity Against Multi-Drug Resistant Bacteria

Novel antimicrobial peptide demonstrates potent activity against carbapenem-resistant bacteria in preclinical testing, advancing toward human trials.

#antimicrobial-peptide #antibiotic-resistance #mdr-bacteria +2
6 min read
Weekly Briefing Dec 17, 2025

Study Shows AOD-9604 Lacks Significant Fat Reduction Efficacy in Humans

Meta-analysis of available human data concludes AOD-9604 does not produce clinically meaningful fat loss, despite continued popularity in the wellness community.

#aod-9604 #weight-loss #clinical-trial +2
6 min read
Weekly Briefing Dec 15, 2025

Tirzepatide SURMOUNT-OSA Trial Confirms Sleep Apnea Improvement

SURMOUNT-OSA trial demonstrates tirzepatide significantly reduces obstructive sleep apnea severity, with nearly half of participants achieving disease resolution.

#tirzepatide #sleep-apnea #osa +2
6 min read
Weekly Briefing Dec 12, 2025

Research Demonstrates SS-31 Mitochondrial Protection in Heart Failure Models

Comprehensive preclinical study shows SS-31 (elamipretide) restores mitochondrial function and improves cardiac performance in multiple heart failure models.

#ss-31 #elamipretide #mitochondria +2
6 min read
Weekly Briefing Dec 10, 2025

Peptide Stapling Technology Enables Oral Delivery of Macrocyclic Therapeutics

New research demonstrates that hydrocarbon-stapled peptides can achieve oral bioavailability exceeding 20%, potentially transforming peptide therapeutic development.

#peptide-stapling #oral-delivery #macrocycle +2
6 min read
Weekly Briefing Dec 8, 2025

Oral Semaglutide 25mg Approved for Type 2 Diabetes with Enhanced Efficacy

FDA approves higher 25mg dose of oral semaglutide for type 2 diabetes, offering glycemic control comparable to injectable formulation without injections.

#semaglutide #oral #rybelsus +2
6 min read
Weekly Briefing Dec 5, 2025

Biotech Develops AI Platform for Accelerated Peptide Drug Discovery

New AI platform claims to reduce peptide drug candidate identification from years to weeks, demonstrating success in generating novel antimicrobial peptides.

#ai #drug-discovery #peptide-design +2
6 min read
Weekly Briefing Dec 3, 2025

Study Shows Tesamorelin Reduces Liver Fat in Patients with HIV-Associated NAFLD

Clinical trial confirms tesamorelin, a growth hormone-releasing hormone analog, significantly reduces hepatic steatosis in HIV patients with metabolic complications.

#tesamorelin #nafld #hiv +2
6 min read
Weekly Briefing Dec 1, 2025

FDA Approves Cagrilintide-Semaglutide Combination for Obesity Treatment

FDA grants approval to Novo Nordisk's CagriSema, combining cagrilintide and semaglutide in a single weekly injection for chronic weight management.

#cagrilintide #semaglutide #fda-approval +2
6 min read
Weekly Briefing Nov 28, 2025

Research Links Dihexa Peptide to Memory Enhancement in Animal Models

New research demonstrates dihexa, a synthetic hexapeptide, enhances memory formation and synaptic plasticity in rodent studies through hepatocyte growth factor signaling.

#dihexa #memory #nootropic +2
6 min read
Weekly Briefing Nov 26, 2025

Peptide-Modified CAR-T Cells Show Enhanced Tumor Penetration in Solid Tumors

Novel approach using tumor-penetrating peptides to enhance CAR-T cell infiltration demonstrates promising results against solid tumors in preclinical and early clinical studies.

#car-t #peptide-conjugate #immunotherapy +2
6 min read
Weekly Briefing Nov 24, 2025

GLP-1 Medication Shortage Easing as Manufacturing Capacity Expands

After more than a year of supply constraints, GLP-1 receptor agonist availability is improving as Novo Nordisk and Eli Lilly bring new manufacturing facilities online.

#glp-1 #drug-shortage #manufacturing +2
6 min read
Weekly Briefing Nov 21, 2025

Injectable Humanin Peptide Shows Neuroprotective Effects in Early Clinical Trial

First-in-human trial of synthetic humanin analog demonstrates safety and preliminary signals of neuroprotective activity, advancing mitochondrial peptide research.

#humanin #neuroprotection #alzheimers +2
6 min read
Guide Nov 21, 2025

What is GHK-Cu?

An introduction to GHK-Cu (copper peptide), the naturally occurring peptide used in skincare. Learn about its evidence for wound healing and anti-aging benefits.

#ghk-cu #copper-peptide #skincare +2
6 min read
Weekly Briefing Nov 19, 2025

Study Reveals Oxytocin Peptide Improves Social Cognition in Autism Spectrum Disorder

Controlled trial demonstrates intranasal oxytocin improves social cognition measures in adults with autism spectrum disorder, though individual response variability remains high.

#oxytocin #autism #social-cognition +2
6 min read
Weekly Briefing Nov 17, 2025

Amycretin Dual-Agonist Peptide Reports Positive Phase 2 Weight Loss Data

Novo Nordisk's amycretin, a novel GLP-1/amylin dual-agonist peptide, demonstrates impressive weight loss results in phase 2 trial, potentially rivaling current leading therapies.

#amycretin #dual-agonist #obesity +2
6 min read
Guide Nov 17, 2025

What is Mounjaro?

An introduction to Mounjaro, the brand name for tirzepatide approved for type 2 diabetes. Learn how this dual GIP/GLP-1 agonist differs from other diabetes medications.

#mounjaro #tirzepatide #diabetes +3
6 min read
Regulatory Nov 15, 2025

Wegovy Pill Launches in US: First Oral GLP-1 for Weight Loss at $149/Month

Novo Nordisk launches the first oral GLP-1 receptor agonist for weight management in the United States, pricing it at $149/month to dramatically expand access to semaglutide therapy.

#semaglutide #oral-glp1 #wegovy +1
6 min read
Safety Nov 14, 2025

Epithalon Safety Concerns

Critical evaluation of epithalon safety claims and evidence quality. Learn why longevity claims are unsupported and what risks exist with this unregulated compound.

#epithalon #safety #longevity +2
6 min read
Weekly Briefing Nov 14, 2025

European Consortium Launches Pan-EU Peptide Research Initiative

European Commission announces major funding initiative for collaborative peptide therapeutics research, uniting academic institutions and industry partners across 15 member states.

#european-union #research-consortium #peptide-therapeutics +2
6 min read
Weekly Briefing Nov 12, 2025

Research Shows GHK-Cu Promotes Stem Cell Differentiation in Wound Healing Model

New research demonstrates copper-binding peptide GHK-Cu enhances mesenchymal stem cell differentiation, suggesting mechanisms for its observed wound healing properties.

#ghk-cu #stem-cells #wound-healing +2
6 min read
Guide Nov 12, 2025

What is MK-677?

An introduction to MK-677, an oral growth hormone secretagogue that was never approved. Learn how it works, research findings, and why development was discontinued.

#mk-677 #ibutamoren #growth-hormone +2
6 min read
Weekly Briefing Nov 10, 2025

Semaglutide SOUL Trial Confirms Cardiovascular Benefits in Diabetic Kidney Disease

The SOUL cardiovascular outcomes trial confirms semaglutide reduces major adverse cardiac events in patients with type 2 diabetes and chronic kidney disease.

#semaglutide #cardiovascular #kidney-disease +2
6 min read
Guide Nov 8, 2025

Why Animal Studies Aren't Enough

Understanding why promising rodent research often fails to translate to human benefits. Learn why over 90% of animal study successes don't become working treatments.

#research #animal-studies #translation +2
6 min read
Weekly Briefing Nov 7, 2025

FDA Grants Breakthrough Designation to Cancer Peptide Vaccine Candidate

FDA awards breakthrough therapy designation to personalized neoantigen peptide vaccine for melanoma, accelerating development of next-generation cancer immunotherapy.

#cancer-vaccine #peptide-vaccine #fda +2
6 min read
Weekly Briefing Nov 5, 2025

Selank Peptide Shows Anxiolytic Effects Comparable to Benzodiazepines in New Study

Russian researchers publish comparative study showing synthetic peptide selank demonstrates anxiety-reducing effects similar to benzodiazepines without sedation or dependence risk.

#selank #anxiety #nootropic +2
6 min read
Weekly Briefing Nov 3, 2025

Eli Lilly Announces $4B Peptide Manufacturing Expansion

Eli Lilly announces $4 billion manufacturing expansion to address GLP-1 demand, with new facilities dedicated to tirzepatide and next-generation peptide production.

#eli-lilly #manufacturing #tirzepatide +2
6 min read
Research Digest Nov 3, 2025

Peptide-Drug Conjugates Advance in Oncology (CBX-12 Phase II)

Phase II results for CBX-12 demonstrate the promise of peptide-drug conjugates in cancer treatment. This targeted delivery approach may improve chemotherapy precision while reducing systemic toxicity.

#peptide-drug-conjugates #pdcs #cbx-12 +1
6 min read
Weekly Briefing Oct 31, 2025

Antimicrobial Peptide LL-37 Shows Wound Healing Benefits

Clinical study demonstrates topical LL-37 accelerates diabetic wound healing by 40%, combining antimicrobial activity with direct tissue repair effects.

#ll-37 #wound-healing #antimicrobial-peptide +2
6 min read
Weekly Briefing Oct 29, 2025

Study Links GLP-1s to Improved Outcomes in Kidney Disease

Large real-world analysis demonstrates GLP-1 agonist users have 28% lower risk of kidney disease progression compared to other diabetes treatments, adding to nephroprotection evidence.

#glp-1 #kidney-disease #ckd +2
6 min read
Safety Oct 29, 2025

GLP-1 Agonist Safety Overview

Clinical trial safety data and post-marketing surveillance findings for GLP-1 receptor agonists including tirzepatide and semaglutide. Covers common side effects, serious adverse events, boxed warnings, and contraindications.

#glp-1 #semaglutide #tirzepatide +2
7 min read
Weekly Briefing Oct 27, 2025

Oral Tirzepatide Formulation Enters Phase 1 Testing

Eli Lilly initiates Phase 1 trials for oral tirzepatide formulation using novel absorption enhancement technology, potentially eliminating the need for weekly injections.

#tirzepatide #oral-delivery #drug-delivery +2
6 min read
Guide Oct 27, 2025

What is LL-37?

An introduction to LL-37, a human antimicrobial peptide with emerging research on immune function. Learn what scientists are investigating and current evidence limitations.

#ll-37 #cathelicidin #antimicrobial +2
6 min read
Weekly Briefing Oct 24, 2025

Research Demonstrates BPC-157 Gut-Brain Axis Modulation

Comprehensive preclinical study reveals BPC-157 modulates gut-brain axis signaling, potentially explaining its diverse reported effects on both gastrointestinal and neurological function.

#bpc-157 #gut-brain-axis #neuroprotection +2
6 min read
Guide Oct 24, 2025

How Do Peptides Work?

An introduction to how peptides function in the body, including receptor binding, signaling, and why structure matters. Learn the science behind peptide medications.

#peptides #mechanism #receptors +2
6 min read
Weekly Briefing Oct 22, 2025

FDA Issues Complete Response Letter for Pemvidutide, Requests More Data

FDA issues complete response letter for pemvidutide's MASH indication, requesting additional efficacy data and longer follow-up before approval consideration.

#pemvidutide #fda #crl +2
6 min read
Research Digest Oct 20, 2025

Peptide PROTACs Emerge as Promising Approach for Cancer Treatment

Researchers demonstrate peptide-based PROTACs can selectively degrade previously undruggable cancer targets, opening new therapeutic possibilities beyond traditional small molecule approaches.

#protacs #cancer #peptide-conjugates +1
6 min read
Weekly Briefing Oct 20, 2025

Retatrutide Triple-Agonist Shows Superior Weight Loss in Direct Comparison

Head-to-head Phase 3 trial demonstrates retatrutide achieves 26.5% weight loss versus 21.8% with tirzepatide, establishing the triple-agonist as the most effective obesity medication tested.

#retatrutide #tirzepatide #weight-loss +2
6 min read
Guide Oct 18, 2025

What is Semaglutide?

An introduction to semaglutide, the GLP-1 agonist behind Ozempic and Wegovy. Learn how it works, what it's approved for, and key facts about this medication.

#semaglutide #glp-1 #ozempic +3
6 min read
Weekly Briefing Oct 17, 2025

Peptide Nasal Spray for Migraine Prevention Enters Phase 2

Novel CGRP-blocking peptide nasal spray enters Phase 2 trials for migraine prevention, offering potential fast-acting alternative to injectable monoclonal antibodies.

#migraine #cgrp #nasal-spray +2
6 min read
Weekly Briefing Oct 15, 2025

Study Shows Epithalon Telomerase Activation in Human Cells

New in-vitro study demonstrates epithalon activates telomerase in human fibroblasts, extending replicative lifespan by 32%, providing mechanistic support for the peptide's anti-aging claims.

#epithalon #telomerase #longevity +2
6 min read
Guide Oct 15, 2025

What is BPC-157?

An introduction to BPC-157, its origins, claims, and important limitations. Learn why it's not FDA-approved and what the research actually shows.

#bpc-157 #recovery #tissue-repair +1
6 min read
Weekly Briefing Oct 13, 2025

CagriSema NDA Filed with FDA for Obesity Treatment

Novo Nordisk files NDA for CagriSema, combining semaglutide with amylin analog cagrilintide, after Phase 3 trials showed up to 25% weight loss in obesity patients.

#cagrisema #cagrilintide #semaglutide +2
6 min read
Guide Oct 10, 2025

Peptide Clinical Trial Phases

Understanding the phases of clinical trials and what each stage tells us about a peptide's development. Learn to interpret trial status and what it really means for safety and efficacy.

#clinical-trials #fda #drug-development +2
6 min read
Weekly Briefing Oct 10, 2025

Japanese Firm Develops Injectable Peptide Hydrogel for Joints

Kyoto-based biotech develops self-assembling peptide hydrogel that provides long-lasting joint lubrication and cartilage support, showing promising results in early trials.

#hydrogel #joint-health #regenerative-medicine +2
6 min read
Weekly Briefing Oct 8, 2025

Research Identifies Biomarkers Predicting GLP-1 Response

Multi-center study identifies genetic and protein biomarkers that predict response to GLP-1 medications, potentially enabling precision prescribing for obesity treatment.

#glp-1 #biomarkers #precision-medicine +2
6 min read
Guide Oct 8, 2025

What is Ipamorelin?

An introduction to ipamorelin, a selective growth hormone secretagogue that was never approved. Learn how it claims to work and why development was discontinued.

#ipamorelin #growth-hormone #ghrp +1
6 min read
Research Digest Oct 6, 2025

Orforglipron Beats Oral Semaglutide Head-to-Head

New Phase 3 data shows orforglipron outperforms oral semaglutide for weight loss in direct comparison, marking a potential shift in the oral GLP-1 landscape.

#orforglipron #semaglutide #oral-glp1 +1
6 min read
Weekly Briefing Oct 6, 2025

Zepbound Approved for Sleep Apnea, Expanding GLP-1 Indications

FDA approves Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity, marking the first medication approved specifically for this condition.

#zepbound #tirzepatide #sleep-apnea +2
6 min read
Weekly Briefing Oct 3, 2025

MOTS-c Mitochondrial Peptide Advances to Human Trials

USC researchers launch first human clinical trial of MOTS-c, a mitochondrial-derived peptide showing remarkable metabolic and longevity benefits in preclinical studies.

#mots-c #mitochondria #longevity +2
6 min read
Research Digest Oct 3, 2025

Retatrutide TRIUMPH-4: 28.7% Weight Loss Combined with Osteoarthritis Pain Relief

Eli Lilly's triple-agonist retatrutide achieves unprecedented 28.7% weight loss while significantly reducing knee osteoarthritis pain in the TRIUMPH-4 trial, demonstrating benefits beyond metabolic effects.

#retatrutide #triple-agonist #obesity +1
7 min read
Weekly Briefing Oct 1, 2025

Peptide-Based Antiviral Shows Broad Coronavirus Efficacy

Stanford researchers develop pan-coronavirus peptide inhibitor that blocks viral entry across SARS-CoV-2 variants and related coronaviruses, offering potential pandemic preparedness tool.

#antiviral #coronavirus #peptide-therapeutics +2
6 min read
Guide Oct 1, 2025

What is Epithalon?

An introduction to epithalon, a synthetic tetrapeptide studied for potential effects on telomeres. Learn about the evidence limitations and why claims should be viewed skeptically.

#epithalon #epitalon #telomeres +2
6 min read
Weekly Briefing Sep 29, 2025

Tirzepatide Shows Heart Failure Benefits in SUMMIT Trial

SUMMIT trial demonstrates tirzepatide reduces heart failure events by 38% in patients with HFpEF and obesity, establishing cardiovascular benefits beyond weight loss.

#tirzepatide #heart-failure #summit-trial +2
6 min read
Guide Sep 29, 2025

What is Retatrutide?

An introduction to retatrutide, the investigational triple agonist showing promising weight loss results. Learn how it differs from tirzepatide and semaglutide.

#retatrutide #triple-agonist #glp-1 +3
6 min read
Regulatory Sep 27, 2025

Pemvidutide Breakthrough Designation for MASH

The FDA has granted Breakthrough Therapy Designation to pemvidutide for MASH treatment. This dual GLP-1/glucagon agonist joins the growing pipeline targeting metabolic liver disease.

#pemvidutide #mash #breakthrough-therapy +1
6 min read
Weekly Briefing Sep 26, 2025

Semax Stroke Recovery: BDNF Mechanism & Neuroprotective Effects

New mechanism study shows semax reduced stroke infarct volume by up to 62% in preclinical models through BDNF upregulation and anti-inflammatory pathways. Evidence grade: low — animal data only.

#semax #neuroprotection #stroke +2
6 min read
Guide Sep 26, 2025

What Are GLP-1 Agonists?

An introduction to the GLP-1 agonist class of medications for diabetes and weight management. Learn how they work, available medications, and what they're used for.

#glp-1 #semaglutide #tirzepatide +3
6 min read
Weekly Briefing Sep 24, 2025

FDA Guidance Tightens Compounding Pharmacy Peptide Oversight

New FDA guidance significantly restricts compounding pharmacy peptide production, citing quality concerns and patient safety risks from unregulated manufacturing.

#fda #compounding #regulation +2
6 min read
Weekly Briefing Sep 22, 2025

Survodutide Phase 3 Results Exceed Expectations for MASH

Survodutide achieves 76% MASH resolution in Phase 3 ACHIEVE trial, confirming the dual GLP-1/glucagon agonist as a leading candidate for liver disease treatment.

#survodutide #mash #phase-3 +2
6 min read
Guide Sep 22, 2025

What Are GH Secretagogues?

An introduction to growth hormone secretagogues, compounds that stimulate the body to release growth hormone. Learn the difference between GHRH analogs and GHRPs.

#growth-hormone #secretagogue #ghrh +2
6 min read
Safety Sep 20, 2025

Melanotan II Safety Warning

Critical safety warnings about Melanotan II from regulatory agencies worldwide. Learn why health authorities have issued alerts about this unapproved tanning peptide.

#melanotan #safety #warning +2
6 min read
Deep Dive Sep 19, 2025

Cell-Penetrating Peptides in Cancer Immunotherapy

Cell-penetrating peptides are emerging as versatile delivery vehicles for cancer immunotherapy. This deep dive explores the science, current research, and clinical potential of CPPs.

#cell-penetrating-peptides #cpps #cancer +1
6 min read
Weekly Briefing Sep 19, 2025

Research Team Develops Heat-Stable Peptide Delivery System

MIT researchers create a heat-stable peptide delivery system that maintains efficacy at temperatures up to 40C for 6 months, potentially transforming global peptide distribution.

#drug-delivery #peptide-stability #formulation +1
6 min read
Weekly Briefing Sep 17, 2025

GLP-1 Agonists Linked to Reduced Dementia Risk in Large Observational Study

Analysis of over 500,000 patients finds GLP-1 receptor agonist use associated with significantly lower dementia incidence compared to other diabetes medications.

#glp-1 #dementia #alzheimers +2
6 min read
Research Digest Sep 17, 2025

Tirzepatide Shows Promising 10-Year Cardiovascular Risk Reduction in SURMOUNT-5 Post-Hoc Analysis

Post-hoc analysis of SURMOUNT-5 data suggests tirzepatide may substantially reduce 10-year cardiovascular disease risk, though prospective outcome trials are needed for confirmation.

#tirzepatide #cardiovascular #surmount-5 +1
6 min read
Weekly Briefing Sep 15, 2025

Peptide Drug Conjugate Shows 40% Tumor Reduction in Phase 2 Trial

Phase 2 results demonstrate a novel peptide-drug conjugate achieves significant tumor reduction in patients with advanced solid tumors expressing the target receptor.

#peptide-drug-conjugate #oncology #clinical-trial +2
6 min read
Research Digest Sep 13, 2025

Oxytocin Optimal Dosing for Autism: Meta-Analysis Examines Social Behavior Effects

A comprehensive meta-analysis of oxytocin trials in autism spectrum disorder suggests dose-dependent effects on social behavior, with implications for future research design and potential therapeutic applications.

#oxytocin #autism #meta-analysis +1
7 min read
Research Digest Sep 12, 2025

Cagrilintide REDEFINE-1: Amylin Monotherapy Validated for Obesity Treatment

REDEFINE-1 trial demonstrates cagrilintide, a long-acting amylin analog, achieves significant weight loss as monotherapy, validating amylin as a standalone obesity treatment target.

#cagrilintide #amylin #redefine-1 +1
6 min read
Weekly Briefing Sep 12, 2025

European Regulators Approve Pemvidutide for MASH Treatment

The European Medicines Agency grants approval for pemvidutide as the first GLP-1/glucagon dual agonist for metabolic dysfunction-associated steatohepatitis (MASH).

#pemvidutide #mash #nafld +3
6 min read
Research Digest Sep 10, 2025

SURMOUNT-5 Results: Tirzepatide Beats Semaglutide by 6.5% in Head-to-Head Weight Loss Trial

The first head-to-head trial comparing tirzepatide and semaglutide for obesity shows tirzepatide achieves 6.5 percentage points greater weight loss, establishing clear efficacy differences.

#tirzepatide #semaglutide #surmount-5 +1
6 min read
Weekly Briefing Sep 10, 2025

New Thymosin Alpha-1 Study Shows Immune Enhancement in Elderly Adults

Clinical study demonstrates that thymosin alpha-1 supplementation enhances immune function markers in elderly adults, with implications for healthy aging.

#thymosin-alpha-1 #immunology #aging +2
6 min read
Weekly Briefing Sep 8, 2025

Novo Nordisk Expands Peptide Manufacturing Capacity with $4B Investment

Novo Nordisk announces major manufacturing expansion with new facilities to address persistent GLP-1 supply constraints and support future growth.

#novo-nordisk #manufacturing #supply-chain +2
6 min read
Guide Sep 8, 2025

What Are Nootropic Peptides?

An introduction to peptides marketed for cognitive enhancement, including Semax, Selank, and Dihexa. Learn what the evidence actually shows versus marketing claims.

#nootropic #cognitive #semax +3
6 min read
Deep Dive Sep 5, 2025

Antimicrobial Peptides Show Cancer-Fighting Potential: A Deep Dive into Early Research

Early research reveals antimicrobial peptides may selectively target cancer cells while leaving healthy tissue intact, offering a potential new avenue for cancer therapeutics.

#antimicrobial-peptides #amps #cancer +1
6 min read
Weekly Briefing Sep 5, 2025

Clinical Trial Links TB-500 Fragment to Accelerated Wound Healing

Results from a controlled clinical trial demonstrate that a thymosin beta-4 fragment significantly accelerates healing in chronic wounds, advancing regenerative peptide therapeutics.

#tb-500 #thymosin-beta-4 #wound-healing +2
6 min read
Weekly Briefing Sep 3, 2025

Biotech Startup Raises $50M for Antimicrobial Peptide Development

A biotechnology company focused on antimicrobial peptides announces significant Series B funding to advance novel treatments against drug-resistant bacteria.

#antimicrobial-peptides #biotech #funding +2
6 min read
Research Digest Sep 3, 2025

BPC-157 IV Pilot Study: First Human Safety Data Emerges

A pilot study provides the first formal human safety data for BPC-157 administered intravenously, marking an important step toward understanding this widely discussed peptide.

#bpc-157 #safety #human-trial +1
6 min read
Deep Dive Sep 1, 2025

BPC-157 Systematic Review: Examining the Musculoskeletal Evidence

A systematic review evaluates the preclinical evidence for BPC-157 in musculoskeletal healing, finding consistent animal data but highlighting the critical absence of human clinical trials.

#bpc-157 #musculoskeletal #systematic-review +1
6 min read
Weekly Briefing Sep 1, 2025

FDA Extends Semaglutide Shortage Designation Amid Persistent Demand

The FDA announces extension of semaglutide shortage designation as demand continues to outpace manufacturing capacity, with implications for compounding and patient access.

#semaglutide #fda #drug-shortage +2
6 min read
Guide Aug 30, 2025

How to Read Peptide Research

A practical guide to evaluating peptide research claims and understanding what studies actually show. Learn to separate promising science from marketing hype.

#research #methodology #critical-thinking +2
6 min read
Weekly Briefing Aug 29, 2025

Research Identifies Novel Longevity Peptide in Centenarians

Scientists discover a mitochondrial-derived peptide at elevated levels in centenarians, potentially opening new avenues for understanding healthy aging.

#longevity #centenarians #mitochondria +2
6 min read
Weekly Briefing Aug 27, 2025

Peptide Therapeutics Market Projected to Hit $80 Billion by 2030

New market analysis projects the global peptide therapeutics market will reach $80 billion by 2030, driven primarily by GLP-1 medications and expanding applications.

#market-analysis #peptide-therapeutics #investment +1
6 min read
Research Digest Aug 27, 2025

Semaglutide Fails Alzheimer's Trials: EVOKE Program Results Disappoint

Novo Nordisk's EVOKE and EVOKE Plus trials fail to show semaglutide slows cognitive decline in early Alzheimer's disease, dampening hopes for GLP-1 agonists as dementia treatments.

#semaglutide #alzheimers #evoke +1
6 min read
Weekly Briefing Aug 25, 2025

Orforglipron Oral GLP-1 Advances to Phase 3 with Expanded Program

Eli Lilly expands phase 3 program for orforglipron, its once-daily oral GLP-1 agonist, after promising phase 2 results demonstrate competitive weight loss efficacy.

#orforglipron #oral-glp1 #eli-lilly +2
6 min read
Guide Aug 25, 2025

What is TB-500?

An introduction to TB-500, a fragment of thymosin beta-4 marketed for tissue repair. Learn about its relationship to the parent compound and evidence limitations.

#tb-500 #thymosin-beta-4 #recovery +2
6 min read
Safety Aug 23, 2025

Growth Hormone Peptide Safety

Safety considerations for unapproved growth hormone-releasing peptides. Learn why caution is warranted with these research compounds.

#growth-hormone #ipamorelin #cjc-1295 +2
6 min read
Research Digest Aug 22, 2025

Pemvidutide IMPACT Results: 59% MASH Resolution in Phase 2 Trial

Altimmune reports pemvidutide achieved 59% MASH resolution without fibrosis worsening in the IMPACT trial, positioning the GLP-1/glucagon dual agonist as a potential breakthrough for liver disease.

#pemvidutide #mash #liver-disease +1
6 min read
Weekly Briefing Aug 22, 2025

Study Finds Peptide-Based Cancer Vaccines Effective in Melanoma Patients

Clinical trial demonstrates significant survival benefit for personalized peptide cancer vaccines in advanced melanoma, validating the neoantigen approach.

#cancer-vaccine #melanoma #immunotherapy +2
6 min read
Weekly Briefing Aug 20, 2025

China Approves First Domestic Tirzepatide Biosimilar

China's drug regulator grants approval to the first domestically manufactured tirzepatide biosimilar, signaling expanded access in the world's largest obesity market.

#tirzepatide #biosimilar #china +2
6 min read
Research Digest Aug 20, 2025

Orforglipron ATTAIN-1: Oral GLP-1 Achieves 12.4% Weight Loss

The ATTAIN-1 trial demonstrates orforglipron, a non-peptide oral GLP-1 agonist, achieves meaningful weight loss rivaling injectable options. A new era for oral obesity treatment may be emerging.

#orforglipron #attain-1 #oral-glp1 +1
6 min read
Weekly Briefing Aug 18, 2025

Amgen's Maritide Shows Promising Phase 2 Weight Loss Data

Amgen presents phase 2 results for maritide, demonstrating significant weight loss with a convenient monthly injection schedule that could differentiate it in the competitive obesity market.

#maritide #amgen #phase-2 +2
6 min read
Guide Aug 18, 2025

Peptide vs Protein: What's the Difference?

Understanding the difference between peptides and proteins, and why it matters for medications and supplements. Learn the size distinction and practical implications.

#peptide #protein #amino-acid +2
6 min read
Safety Aug 16, 2025

Tirzepatide Safety Profile

Safety information for tirzepatide including common side effects, warnings, and contraindications. Based on SURPASS and SURMOUNT clinical trial data with over 10,000 patient exposures.

#tirzepatide #mounjaro #zepbound +2
6 min read
Weekly Briefing Aug 15, 2025

New Research Links GLP-1 Agonists to Reduced Alcohol Cravings

Published research reveals potential mechanism by which GLP-1 receptor agonists may reduce alcohol consumption, with implications for addiction treatment.

#glp-1 #semaglutide #alcohol +2
6 min read
Guide Aug 15, 2025

What is Rybelsus?

An introduction to Rybelsus, the oral tablet form of semaglutide for type 2 diabetes. Learn how this unique peptide formulation allows for oral administration.

#rybelsus #semaglutide #oral +3
6 min read
Weekly Briefing Aug 13, 2025

FDA Issues Warning on Quality Concerns with Compounded Semaglutide Products

The FDA releases safety communication highlighting quality issues identified in compounded semaglutide products, urging caution amid ongoing brand-name supply constraints.

#semaglutide #fda #compounding +2
6 min read
Safety Aug 13, 2025

PT-141 (Vyleesi) Safety Profile

Safety information for FDA-approved PT-141 (bremelanotide/Vyleesi) for HSDD. Complete side effects, warnings, and contraindications from clinical trial data.

#pt-141 #bremelanotide #vyleesi +3
6 min read
Weekly Briefing Aug 11, 2025

CagriSema Phase 3 Trial Achieves Primary Endpoint with Record Weight Loss

Novo Nordisk's CagriSema combination therapy hits primary endpoint in phase 3 trial, demonstrating weight loss exceeding 25% and positioning the company for regulatory submission.

#cagrisema #cagrilintide #semaglutide +3
6 min read
Weekly Briefing Aug 8, 2025

European Biotech Advances Oral BPC-157 Formulation Toward Clinical Trials

A European biotechnology company announces progress on an oral formulation of BPC-157, potentially bringing the research peptide closer to formal clinical development.

#bpc-157 #oral-peptide #drug-development +2
6 min read
Guide Aug 8, 2025

What is Tirzepatide?

An introduction to tirzepatide, a dual GIP/GLP-1 receptor agonist used for type 2 diabetes and weight management. Learn how it works, what the research shows, and key facts you should know.

#tirzepatide #mounjaro #zepbound +4
6 min read
Weekly Briefing Aug 6, 2025

Eli Lilly Reports Record Q2 Revenue Surge Driven by Tirzepatide Demand

Eli Lilly announces record quarterly revenue as tirzepatide products Mounjaro and Zepbound drive unprecedented growth in the metabolic disease market.

#tirzepatide #eli-lilly #revenue +3
6 min read
Guide Aug 6, 2025

What Are Recovery Peptides?

An introduction to peptides marketed for tissue repair and recovery, including BPC-157 and TB-500. Learn what's claimed versus what the evidence actually shows.

#recovery #bpc-157 #tb-500 +2
6 min read
Weekly Briefing Aug 4, 2025

Retatrutide Phase 3 Obesity Trial Completes Enrollment Milestone

Eli Lilly announces completion of enrollment for pivotal phase 3 obesity trials of retatrutide, the triple-agonist peptide showing unprecedented weight loss results.

#retatrutide #phase-3 #obesity +2
6 min read
Research Digest Aug 4, 2025

Survodutide Phase 2 MASH: 62% Improvement at 4.8mg

Phase 2 data shows survodutide achieving 62% MASH resolution at 4.8mg dose, with even higher rates at 6.0mg. The dual GLP-1/glucagon agonist shows promise for liver disease.

#survodutide #mash #liver-disease +1
6 min read
Safety Aug 2, 2025

Semaglutide Safety Profile

Safety information for semaglutide including common side effects, warnings, and contraindications. Based on extensive clinical trial data with tens of thousands of patients.

#semaglutide #ozempic #wegovy +2
6 min read
Safety Jul 30, 2025

General Safety: Unregulated Peptides

Important safety information about using peptides from unregulated sources. Learn about product quality, contamination risks, and why regulation matters.

#safety #unregulated #research-peptides +2
6 min read
Guide Jul 28, 2025

How Do GLP-1 Agonists Work?

A clear explanation of how GLP-1 receptor agonists produce their effects on metabolism and appetite. Learn the science behind these evidence-backed medications.

#glp-1 #semaglutide #tirzepatide +3
6 min read
Guide Jul 25, 2025

What is CJC-1295?

An introduction to CJC-1295, a modified GHRH analog designed for longer-lasting effects. Learn about the two forms (with and without DAC) and why development was discontinued.

#cjc-1295 #ghrh #growth-hormone +2
6 min read
Guide Jul 23, 2025

Are Peptides Safe?

An honest overview of peptide safety, distinguishing between approved medications and research compounds. The answer depends entirely on which peptide and from what source.

#safety #fda #research-peptides +2
6 min read
Guide Jul 19, 2025

Peptide Evidence Levels Explained

Understanding how we evaluate and grade the evidence behind peptide claims at PepCodex. Learn the difference between Very High and Very Low evidence levels.

#evidence #research #fda +2
6 min read
Research Digest Jul 18, 2025

GLP-1 Kidney Protection Confirmed: Meta-Analysis Shows 21% Reduction in Renal Events

A comprehensive meta-analysis confirms GLP-1 receptor agonists reduce major kidney events by 21%, establishing nephroprotection as a class effect beyond glucose control.

#glp-1 #kidney-disease #ckd +1
6 min read
Safety Jul 16, 2025

AOD-9604 Safety Information

Safety information for AOD-9604, which failed clinical trials but is still sold illegally. Learn why this peptide's development was discontinued and risks of current use.

#aod-9604 #safety #failed-trials +1
6 min read
Guide Jul 14, 2025

What is Sermorelin?

An introduction to sermorelin, a GHRH analog that was once FDA-approved for pediatric growth hormone deficiency. Learn about its history and current availability.

#sermorelin #ghrh #growth-hormone +1
6 min read
Regulatory Jul 12, 2025

FDA Tightens Peptide Compounding Rules: BPC-157 and TB-500 Impacted

The FDA finalizes guidance restricting compounding of certain peptides including BPC-157 and TB-500, citing safety concerns and lack of approved drug applications.

#bpc-157 #tb-500 #fda +1
6 min read
Guide Jul 11, 2025

What is Wegovy?

An introduction to Wegovy, the brand name for semaglutide approved for weight management. Learn what clinical trials show and how it differs from Ozempic.

#wegovy #semaglutide #weight-loss +3
6 min read
Guide Jul 7, 2025

What is Zepbound?

An introduction to Zepbound, the brand name for tirzepatide approved for weight management. Learn what clinical trials show about this dual GIP/GLP-1 agonist for obesity.

#zepbound #tirzepatide #weight-loss +4
6 min read
Guide Jul 5, 2025

What is Humanin?

An introduction to humanin, a naturally occurring mitochondrial-derived peptide with protective properties. Learn about this active area of longevity research.

#humanin #mitochondria #longevity +2
6 min read
Guide Jul 2, 2025

What is Thymalin?

An introduction to thymalin, a thymic peptide extract studied for immune function. Learn about its origins in Russian bioregulator research and evidence limitations.

#thymalin #thymus #immune +2
6 min read
Regulatory Jun 30, 2025

CagriSema NDA Filed: First GLP-1 + Amylin Combo Achieves 23% Weight Loss

Novo Nordisk submits New Drug Application for CagriSema, combining semaglutide with the amylin analog cagrilintide to achieve unprecedented 23% average weight loss in trials.

#cagrisema #cagrilintide #semaglutide +2
6 min read
Research Digest Jun 28, 2025

FLOW Trial Landmark: Semaglutide Kidney Protection, Stopped Early

The FLOW trial was stopped early after semaglutide demonstrated significant kidney protection in patients with type 2 diabetes and chronic kidney disease. This landmark finding may expand semaglutide's therapeutic role.

#semaglutide #flow-trial #kidney-disease +1
7 min read
Safety Jun 27, 2025

Tesamorelin Safety Profile

Safety information for FDA-approved tesamorelin (Egrifta) for HIV lipodystrophy. Complete side effects, warnings, and contraindications from clinical data.

#tesamorelin #egrifta #safety +2
6 min read
Regulatory Jun 25, 2025

Oral Semaglutide Approved for Cardiovascular Risk Reduction: Rybelsus Gains New Indication

FDA approves oral semaglutide (Rybelsus) for cardiovascular risk reduction in type 2 diabetes, marking the first oral GLP-1 with this indication based on SOUL trial results.

#semaglutide #rybelsus #cardiovascular +1
6 min read
Deep Dive Jun 21, 2025

Thymosin Alpha-1 and Aging: Understanding Immunosenescence and Immune Restoration

Thymosin alpha-1 may help restore declining immune function with age. We examine the evidence for this thymic peptide's role in combating immunosenescence.

#thymosin-alpha-1 #aging #immunosenescence +1
6 min read
Regulatory Jun 16, 2025

Generic Saxenda FDA Approval: First Generic GLP-1 for Weight Loss

The FDA has approved the first generic version of Saxenda (liraglutide), potentially expanding access to GLP-1 therapy for weight management. Here's what this means.

#liraglutide #saxenda #generic +1
6 min read
Guide Jun 14, 2025

What is Ozempic?

An introduction to Ozempic, the brand name for semaglutide approved for type 2 diabetes. Learn how it differs from Wegovy and what it's prescribed for.

#ozempic #semaglutide #diabetes +2
6 min read
Guide Jun 13, 2025

What is PT-141?

An introduction to PT-141 (bremelanotide/Vyleesi), the FDA-approved treatment for HSDD. Learn how it works, who it's for, and what to expect from this medication.

#pt-141 #bremelanotide #vyleesi +2
6 min read
Guide Jun 11, 2025

What Are Longevity Peptides?

An introduction to peptides marketed for anti-aging and longevity, including Epitalon and thymic peptides. Learn what science actually supports versus marketing claims.

#longevity #anti-aging #epithalon +2
6 min read
Research Digest Jun 9, 2025

Semaglutide Reduces Alcohol Cravings in Phase 2 Trial: New Hope for Alcohol Use Disorder

Phase 2 trial data suggests semaglutide may significantly reduce alcohol cravings and consumption, opening a potential new therapeutic avenue for alcohol use disorder.

#semaglutide #alcohol-use-disorder #addiction +1
6 min read
Guide Jun 7, 2025

What is Dihexa?

An introduction to dihexa, an experimental nootropic peptide studied for cognitive effects. Learn why claims should be viewed with extreme caution given the lack of human data.

#dihexa #nootropic #cognitive +2
6 min read
Guide Jun 6, 2025

What is Tesamorelin?

An introduction to tesamorelin (Egrifta), the FDA-approved GHRH analog for HIV lipodystrophy. Learn how it works and its specific medical applications.

#tesamorelin #egrifta #ghrh +2
6 min read
Guide Jun 4, 2025

What is Melanotan II?

An introduction to Melanotan II, the unapproved tanning peptide with serious safety warnings. Learn why regulatory agencies have issued alerts about this compound.

#melanotan #tanning #research-peptide +1
6 min read
Safety Jun 2, 2025

Recovery Peptide Safety (BPC-157, TB-500)

Safety considerations for unapproved recovery peptides BPC-157 and TB-500. Learn why these peptides carry unknown risks and what the evidence limitations mean for safety.

#bpc-157 #tb-500 #safety +2
6 min read

Never Miss a Briefing

Subscribe to receive weekly peptide research updates, regulatory news, and clinical trial analysis directly in your inbox.

Subscribe to Newsletter